231 related articles for article (PubMed ID: 23352248)
1. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Semin Arthritis Rheum; 2013 Jun; 42(6):562-6. PubMed ID: 23352248
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
[TBL] [Abstract][Full Text] [Related]
3. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
5. Investigation of pegloticase-associated adverse events from a nationwide reporting system database.
Gentry WM; Dotson MP; Williams BS; Hartley M; Stafford KR; Bottorff MB; Gandhi PK
Am J Health Syst Pharm; 2014 May; 71(9):722-7. PubMed ID: 24733135
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
8. Potential for linezolid-related blindness: a review of spontaneous adverse event reports.
Brown J; Aitken SL; van Manen RP
Pharmacotherapy; 2011 Jun; 31(6):585-90. PubMed ID: 21923442
[TBL] [Abstract][Full Text] [Related]
9. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
Khadem TM; van Manen RP; Brown J
Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy.
Knudsen JF; Sokol GH; Flowers CM
J Clin Pharm Ther; 2008 Oct; 33(5):513-9. PubMed ID: 18834366
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
12. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA; Humphries JE; Crean S; Reynolds MW
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
[TBL] [Abstract][Full Text] [Related]
13. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
16. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
Johann-Liang R; Wyeth J; Chen M; Cope JU
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
[TBL] [Abstract][Full Text] [Related]
17. Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature.
Logan JK; Wickramaratne Senarath Yapa S; Harinstein L; Saluja B; Muñoz M; Sahajwalla C; Neuner R; Seymour S
Pharmacotherapy; 2020 Feb; 40(2):125-132. PubMed ID: 31885095
[TBL] [Abstract][Full Text] [Related]
18. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
Huang L; Zalkikar J; Tiwari RC
J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat (Uloric) for chronic treatment of gout.
Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
[TBL] [Abstract][Full Text] [Related]
20. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
